US Stock MarketDetailed Quotes
NWBO Northwest Biotherapeutics
- 0.299000
- +0.013000+4.55%
15min DelayClose Oct 15 16:00 ET
373.22MMarket Cap-4271P/E (TTM)
0.300000High0.280000Low1.60MVolume0.286000Open0.286000Pre Close468.71KTurnover0.14%Turnover RatioLossP/E (Static)1.25BShares0.92900052wk High-4.90P/B340.07MFloat Cap0.25310052wk Low--Dividend TTM1.14BShs Float112.000000Historical High--Div YieldTTM6.99%Amplitude0.140000Historical Low0.292000Avg Price1Lot Size
Northwest Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -40.59%-16.2M | -10.38%-12.41M | -1.63%-53.64M | -91.64%-16.96M | 13.64%-13.92M | 22.37%-11.52M | 13.33%-11.24M | -37.80%-52.78M | 21.31%-8.85M | -129.83%-16.12M |
| Net income from continuing operations | -23.68%-17.87M | -71.91%-18.31M | 40.40%-62.6M | 33.14%-18.92M | 43.44%-18.58M | 51.30%-14.45M | 25.06%-10.65M | -158.64%-105.03M | -121.23%-28.3M | -172.17%-32.85M |
| Operating gains losses | -509.59%-1.5M | 182.97%2.05M | -92.83%2.05M | -77.50%2.81M | -89.34%1.35M | -91.64%365K | -160.21%-2.47M | 111.92%28.51M | 108.56%12.47M | 121.59%12.63M |
| Depreciation and amortization | 22.57%516K | 25.62%505K | 15.53%1.73M | 10.21%421K | 31.10%489K | -28.03%421K | 151.25%402K | 155.97%1.5M | 172.86%382K | 145.39%373K |
| Other non cash items | -32.16%424K | 12.91%682K | -10.52%2.45M | -74.96%157K | 76.74%1.06M | -10.71%625K | -25.34%604K | -7.12%2.74M | -31.33%627K | -11.21%602K |
| Change In working capital | -32.71%833K | 6,172.22%3.28M | -151.26%-3.7M | -247.18%-5.02M | 161.67%140K | -63.75%1.24M | -108.84%-54K | 164.55%7.21M | 590.65%3.41M | -105.90%-227K |
| -Change in prepaid assets | 1,246.43%377K | 32.72%-477K | 226.20%501K | -245.98%-301K | 6,279.17%1.48M | 132.18%28K | -256.28%-709K | -111.42%-397K | -124.03%-87K | -101.13%-24K |
| -Change in payables and accrued expense | -64.64%413K | 486.91%3.72M | -164.65%-4.43M | -239.68%-4.84M | -555.92%-1.38M | -66.51%1.17M | 527.72%634K | 1,246.73%6.85M | 414.42%3.47M | -112.22%-211K |
| -Change in other current assets | -200.00%-2K | 50.00%-8K | -101.92%-12K | 112.50%1K | 103.70%1K | 110.53%2K | -102.36%-16K | 449.16%625K | -142.11%-8K | -235.00%-27K |
| -Change in other current liabilities | 12.50%45K | 16.22%43K | 79.26%242K | 237.84%125K | 14.29%40K | 21.21%40K | 23.33%37K | 419.23%135K | 37.04%37K | 275.00%35K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -40.59%-16.2M | -10.38%-12.41M | -1.63%-53.64M | -91.64%-16.96M | 13.64%-13.92M | 22.37%-11.52M | 13.33%-11.24M | -37.80%-52.78M | 21.31%-8.85M | -129.83%-16.12M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 58.29%-521K | 82.07%-239K | -18.44%-3.44M | 80.65%-418K | -58.33%-437K | -206.13%-1.25M | -2,198.28%-1.33M | 51.75%-2.9M | -39.09%-2.16M | 89.74%-276K |
| Net PPE purchase and sale | 58.29%-521K | 82.07%-239K | -18.44%-3.44M | 80.65%-418K | -58.33%-437K | -206.13%-1.25M | -2,198.28%-1.33M | 51.75%-2.9M | -39.09%-2.16M | 89.74%-276K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 58.29%-521K | 82.07%-239K | -18.44%-3.44M | 80.65%-418K | -58.33%-437K | -206.13%-1.25M | -2,198.28%-1.33M | 51.75%-2.9M | -39.09%-2.16M | 89.74%-276K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 98.40%17.14M | -3.95%12.09M | 25.71%52.76M | 26.99%14.42M | 5.14%17.12M | -17.03%8.64M | 220.97%12.58M | -12.81%41.97M | -52.04%11.35M | 82.58%16.29M |
| Net issuance payments of debt | 835.80%9.75M | -28.28%7.1M | 29,588.29%32.95M | 10,670.71%10.47M | 135.67%11.55M | 181.09%1.04M | 390.72%9.9M | -99.53%111K | -100.81%-99K | 4,052.54%4.9M |
| Net common stock issuance | ---- | ---- | --0 | --0 | --0 | ---- | ---- | 132.56%9.47M | --0 | --0 |
| Net preferred stock issuance | 81.78%4.31M | 51.95%3.62M | -28.60%13.33M | -55.81%3.43M | -52.83%5.14M | --2.37M | --2.39M | --18.67M | --7.77M | --10.9M |
| Proceeds from stock option exercised by employees | -86.34%180K | 428.63%1.31M | -84.61%1.72M | -89.37%119K | -93.36%32K | -75.46%1.32M | -94.07%248K | -44.15%11.16M | -85.78%1.12M | -94.00%482K |
| Net other financing activities | --0 | 0.00%50K | 85.39%4.76M | --400K | --400K | --3.91M | --50K | 926.40%2.57M | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 98.40%17.14M | -3.95%12.09M | 25.71%52.76M | 26.99%14.42M | 5.14%17.12M | -17.03%8.64M | 220.97%12.58M | -12.81%41.97M | -52.04%11.35M | 82.58%16.29M |
| Net cash flow | ||||||||||
| Beginning cash position | -59.97%2.48M | -69.48%2.13M | -54.08%6.97M | -35.31%6.1M | -70.52%1.42M | -11.09%6.19M | -54.08%6.97M | 51.95%15.17M | 145.70%9.43M | 28.55%4.83M |
| Current changes in cash | 110.16%420K | -5,700.00%-560K | 68.52%-4.32M | -965.79%-2.96M | 2,662.04%2.77M | 14.59%-4.13M | 100.11%10K | -459.06%-13.71M | -96.85%342K | 86.22%-108K |
| Effect of exchange rate changes | 97.32%-17K | 216.33%912K | -109.50%-523K | 63.95%-1.01M | -59.46%1.91M | -123.47%-635K | -187.21%-784K | 302.41%5.51M | -706.49%-2.8M | 445.48%4.7M |
| End cash Position | 102.32%2.88M | -59.97%2.48M | -69.48%2.13M | -69.48%2.13M | -35.31%6.1M | -70.52%1.42M | -11.09%6.19M | -54.08%6.97M | -54.08%6.97M | 145.70%9.43M |
| Free cash flow | -30.92%-16.72M | -0.58%-12.65M | -2.51%-57.07M | -57.83%-17.38M | 12.43%-14.36M | 16.26%-12.77M | 3.48%-12.57M | -25.64%-55.68M | 13.99%-11.01M | -68.94%-16.39M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data